Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model.
Monte
Scott V
SV
CPL Associates, LLC, Amherst, New York 14226 , USA. smonte@cplassociates.com
Schentag
Jerome J
JJ
Adelman
Martin H
MH
Paladino
Joseph A
JA
D000284:Administration, Oral; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D001794:Blood Pressure; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use*; D007408:Intestinal Absorption; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012016:Reference Values; D016896:Treatment Outcome
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL